FDA DEVICE FACTS
Lumicell Direct Visualization System (DVS)
Lumicell, Inc.
Verified FDA Record identity for medical-device development research. This overview uses only fields stated in the FDA Record and is not a Device Description.医療機器開発の調査用に、確認済みの FDA Record の識別情報を示しています。この概要は FDA Record に記載された項目だけによるもので、機器説明ではありません。
Indications for use
The combination product consists of an optical imaging agent, LUMISIGHT (pegulicianine) for injection (NDA 214511), and a fluorescence imaging device, the Lumicell Direct Visualization System (DVS). The Lumicell Direct Visualization System is intended for use in adults with breast cancer as an adjunct for the intraoperative detection of cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy surgery. The Lumicell DVS is used with LUMISIGHT for fluorescence imaging of the lumpectomy cavity. LUMISIGHT Indications for Use: LUMISIGHT is an optical imaging agent indicated for fluorescence imaging in adults with breast cancer as an adjunct for the intraoperative detection of
cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy surgery.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。